Non-sedating dexmedetomidine treatment regimens
US11890272B2 · kind B2 · utility
1Cited by
143References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 23, 2022 |
| Grant date | Feb 6, 2024 |
| Priority date | — |
| Expiry date | Nov 23, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.